Spots Global Cancer Trial Database for Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Official Title: Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation

Study ID: NCT02196857

Conditions

Leukemia

Interventions

Azacytidine

Sorafenib

Study Description

Brief Summary: The goal of this clinical research study is to learn if 5-azacitidine and sorafenib can help to control the disease in patients with Acute Myeloid Leukemia (AML) and high risk Myelodisplastic Syndrome (MDS) with FLT3-ITD mutation. The safety of this drug combination will also be studied.

Detailed Description: Study Drug Administration: If you are found to be eligible to take part in this study, you will receive 5-azacitidine either as an injection under the skin or by vein on Days 1-7 of each 28-day cycle. If by vein, the infusion will take about 10-40 minutes. You will take sorafenib by mouth 2 times a day about 12 hours apart, with at least 1 cup (8 ounces) of water on an empty stomach, every day. If you vomit a dose, do not make it up. You should wait and take your next scheduled dose. Each study cycle may last a little longer than 28 days, depending on how you are doing. Study Visits: Each week, blood (about 1 tablespoon) will be drawn for routine tests. Each week for the first 6 weeks, and then as often as your doctor thinks it is needed, you will have your blood pressure measured. Before each cycle, you will have a physical exam. Before every 2-4 cycles, you will have a bone marrow aspirate to check the status of the disease. Length of Study: You may continue taking the study drugs for as long as your doctor thinks it is in your best interest. You will no longer be able to take the study drugs if the disease gets worse or intolerable side effects occur, or if you are unable to follow study directions. Your participation on the study will be over after the follow-up visits. End-of-Study Visit: After you have stopped taking the study drugs, the following tests and procedures will be performed: * You will have a physical exam. * You will have a bone marrow aspirate to check the status of disease. * Blood (about 2 tablespoons) will be drawn for routine tests. Follow-Up Visits: After your end-of-study visit, you will return to the clinic every 3 months and have the following tests and procedures: * You will have a physical exam. * Blood (about 2 tablespoons) will be drawn for routine tests. This is an investigational study. Sorafenib is FDA approved and commercially available for the treatment of kidney cancer and liver cancer. 5-azacitidine is FDA approved for the treatment of MDS, but combining it with sorafenib is investigational. The study doctor can tell you how the study drugs are designed to work. Up to 52 participants will be enrolled in this study. All will take part at MD Anderson.